Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$51 Mln
P/E Ratio
--
P/B Ratio
10.19
Industry P/E
--
Debt to Equity
0
ROE
-0.04 %
ROCE
--
Div. Yield
0 %
Book Value
-2.02
EPS
-5.36
CFO
$-346.51 Mln
EBITDA
$-386.46 Mln
Net Profit
$-447.38 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
OUTLOOK THERAPEUTICS INC (OTLK)
| -19.05 | 2.34 | -23.12 | -81.34 | -64.36 | -35.21 | -- |
|
BSE Sensex*
| 2.45 | 3.29 | 6.36 | 8.72 | 12.16 | 20.36 | 11.42 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
OUTLOOK THERAPEUTICS INC (OTLK)
| -75.73 | -63.52 | -20.59 | 4.62 | 120.34 | -85.25 | -61.34 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 66.44 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product... formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey. Read more
Independent Executive Chairman
Mr. Ralph H. Thurman
Independent Executive Chairman
Mr. Ralph H. Thurman
Headquarters
Iselin, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of OUTLOOK THERAPEUTICS INC (OTLK) stood at $ 32,673,472 Mln as on 31-Dec-24
The share price of OUTLOOK THERAPEUTICS INC (OTLK) is $1.53 (NASDAQ) as of 25-Apr-2025 16:00 EDT. OUTLOOK THERAPEUTICS INC (OTLK) has given a return of -64.36% in the last 3 years.
OUTLOOK THERAPEUTICS INC (OTLK) has a market capitalisation of $ 51 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of OUTLOOK THERAPEUTICS INC (OTLK) is 10.19 times as on 25-Apr-2025, a 345% premium to its peers’ median range of 2.29 times.
Since, TTM earnings of OUTLOOK THERAPEUTICS INC (OTLK) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the OUTLOOK THERAPEUTICS INC (OTLK) and enter the required number of quantities and click on buy to purchase the shares of OUTLOOK THERAPEUTICS INC (OTLK).
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.
The CEO & director of Mr. Ralph H. Thurman. is OUTLOOK THERAPEUTICS INC (OTLK), and CFO & Sr. VP is Mr. Ralph H. Thurman.
There is no promoter pledging in OUTLOOK THERAPEUTICS INC (OTLK).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| OUTLOOK THERAPEUTICS INC (OTLK) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
5615.69
|
|
Net Margin(%)
|
-27515.73
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of OUTLOOK THERAPEUTICS INC (OTLK) was $0 Mln.
$-0.02
(
